Navigation Links
For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibb's Orencia
Date:7/22/2009

WALTHAM, Mass., July 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed rheumatologists' perception of Bristol-Myers Squibb's Orencia is low among rheumatoid arthritis agents. Rheumatologists are less satisfied with the agent when compared to tumor necrosis factor-alpha (TNF-alpha) inhibitors across the top drivers of perception such as inducing remission, improving symptoms and slowing the progression of structural damage. They are also less satisfied with Orencia's affordability and number of reimbursement restrictions compared to other rheumatoid arthritis brands.

In contrast, surveyed patients who are currently taking or have taken Orencia perceive the agent second best out of the nine surveyed brands. Patients are satisfied with Orencia because of its ability to eliminate symptoms and lessen disability when compared to TNF-alpha inhibitors. However, this high perception may be attributed to the fact that an overwhelmingly majority of Orencia patients have switched to the drug after failing treatment with a TNF-alpha inhibitor.

The new report entitled Brand Perceptions in Rheumatoid Arthritis also finds that Orencia's physician-targeted messages were the two least appealing messages among the surveyed agents. Instead of targeting key resonance drivers such as improving joint symptoms, slowing progression of joint damage and helping patients function in basic daily and social activities, Orencia's lowest-ranked message targets copays and insurance coverage.

Orencia's patient-targeted message of 'Oh, yes I can!' ranks first among patients. This message encompasses many of patients' key resonance drivers, emphasizing the ability to improve quality of life as well as being simple and easy to remember.

"Orencia's consumer marketing group is doing a great job with the 'Oh, yes I can!' campaign. The greatest percentage of patients we surveyed correctly matched Orencia to its message and found the message to be the most appealing among all rheumatoid arthritis brands," stated Nicole Westphal, Ph.D., analyst and product manager at Decision Resources. "However, Orencia's physician marketing group has a long way to go if it wants to succeed in building positive brand perception among rheumatologists. Messages targeted at physicians should emphasize slowing progression of joint damage and helping patients function in basic daily and social activities."

About Brand Perception Series

Decision Resources' Brand Perception Series quantitatively analyzes physician and patient brand perception and message resonance. The findings are driven by extensive primary research and offer clients an unbiased, comprehensive, cost-effective solution to understanding the full competitive brand landscape.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Gisselle Morales                             Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    gmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Zucker Hillside Researchers to Receive Large Federal Grant to Test for the Early Treatment of Schizophrenia
2. Varian Medical Systems Receives 510(k) Clearance for Fast and Accurate Acuros(TM) Radiotherapy Treatment Planning Capability
3. Fractional co2 Laser Offers Cosmetic Treatments with Minimal Downtime For Melbourne Patients
4. Earlier HIV antiviral treatment can be cost effective in areas of limited resources
5. New Alzheimers Treatment Could Be on the Horizon
6. New strategy in tumor treatment
7. Earlier HIV Treatment Could Save Lives Worldwide
8. For Treatment of Type 2 Diabetes, 89 Percent of Surveyed Endocrinologists Identify a Need for Additional GLP-1 Analogues and 71 Percent Say the Same About DPP-IV Inhibitors
9. -Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments-
10. Lumenis UltraPulse TotalFX Treatment Featured on ABCNews 20/20 as a Secret Weapon for Treating for Burn Scars
11. Innovative Prostate Cancer Treatment Known as Sonablate(R) HIFU Now Available at Third Site in India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Georgia State University College ... academic programs. , Answering to the increasing demand for curricular specializations, the Certificate ... and environmental and land use law. ,  , “The demand for lawyers with ...
(Date:5/26/2016)... ... May 26, 2016 , ... On Memorial Day, Hope For ... their lives in military battle for the country. The nonprofit Hope For Heroes ... more programs that empower independence for disabled military veterans, as well as police, firemen, ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... one that has a significant negative impact on long-term patient survival, reports a ... The results, published online this week in the Journal of Thoracic and Cardiovascular ...
(Date:5/26/2016)... ... 2016 , ... MadgeTech will be showcasing its line of data logging ... at the MadgeTech headquarters. With products sold in more than 100 countries around the ... NASA. , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech data ...
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. James Maisel will ... Long Island Chapter on June 4, 2016, 1:30-3:30 pm at the Farmingdale Public ... Retina Group of New York , is a Board Certified ophthalmologist who ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... WELLESLEY, Massachusetts , May 26, 2016 ... sequencing (NGS) has matured into an essential life science ... research and development applications. BCC Research reveals in its ... of a second growth phase, one powered by a ... applied fields.      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ...
(Date:5/25/2016)... May 25, 2016 According to ... Type (3D, 2D, 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic ... User (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast to ... Medical Animation Market for the forecast period of 2016 ... 301.3 Million by 2021 from USD 117.3 Million in ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, ... QGEN ; Frankfurt Prime Standard: QIA) today announced that the ... Therawis Diagnostics GmbH to develop and commercialize predictive assays in ... PITX2 as a marker to predict effectiveness of anthracycline treatment ... "We are pleased to partner with Therawis, which developed ...
Breaking Medicine Technology: